Pharma: Clinic Roundup
Thursday, June 13, 2013
Grupo Ferrer Internacional SA, of Barcelona, Spain, completed a global Phase III trial evaluating ozenoxacin formulated as a topical treatment in adult and in pediatric patients 2 years and older with impetigo.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.